DNER and neurodegenerative disease: Resolving potential neurological benefits and/or consequences of BET inhibition in different contexts including in diverse brain cell types and developmental stages is essential as these drugs are currently in use in clinical trials for cancer and are proposed for the treatment of developmental as well as degenerative diseases (Korb et al., 2015; Wang et al., 2021a).